Risk factors and outcomes of cytomegalovirus (CMV) reactivation in critically ill, non-immunosuppressed patients in the intensive care unit

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036637

Enrollment

500

Registered

2025-04-09

Start date

2025-03-28

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B25.9

Interventions

Group 1: Adults admitted to the anesthesiological intensive care unit between 2020-2024, sepsis according to Sepsis-3 criteria, CMV reactivation without pre-existing immunosuppression or known HIV inf

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Admission to the anesthesiological intensive care unit, sepsis according to Sepsis-3 criteria, CMV reactivation

Exclusion criteria

Exclusion criteria: Pre-existing immunosuppression, known HIV infection

Design outcomes

Primary

Measure	Time frame
30 day mortality	—

Secondary

Measure	Time frame
Need for lung replacement therapy (ECMO) (yes/no), duration of lung replacement therapy, ventilation duration, ICU stay duration, hospital stay duration (all previously mentioned in days), need for renal replacement therapy (yes/no), and frequency of gastrointestinal hemorrhages (yes/no)	—

Countries

Germany

Contacts

Public ContactNina Vanessa Pirschtat

Universitätsmedizin Essen

ninavanessa.pirschtat@uk-essen.de+49 201 723 84419

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026